Clinical2025
13-week Phase 2 study (n=125): dose-dependent mean weight loss up to 13.8% from baseline (12.4% vs placebo) at 150 mg/day oral, with mostly mild adverse events.
Oral administration (no injections)
clinical
0 views
Bioglutide
Bioglutide (NA-931) is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors simultaneously.
Overview
Bioglutide (NA-931) is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. Developed by Biomed Industries, this small molecule derived from a cyclic IGF-1 fragment demonstrates remarkable oral bioavailability and blood-brain barrier penetration. Phase 2 clinical trials showed up to 13.8% body weight reduction in 13 weeks while preserving muscle mass - a significant advantage over existing GLP-1 therapies. Currently in Phase 2b/3 trials for obesity and type 2 diabetes.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
NA-931Bioglutide (research product name)quadruple receptor agonist NA-931
Status: Investigational drug - not yet FDA approved; Phase 2b/3 trials for obesity and type 2 diabetes
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Obesity and weight managementType 2 diabetesOral incretin-based therapyMetabolic disease
Available Evidence
Human
NA-931 (marketed to researchers as 'Bioglutide') is an oral quadruple receptor agonist (IGF-1, GLP-1, GIP and glucagon receptors) in Phase 2 development. A 13-week randomized, double-blind, placebo-controlled study in 125 adults with obesity or overweight plus comorbidity reported dose-dependent mean body-weight reductions of up to 13.8% from baseline (12.4% relative to placebo) at 150 mg daily, with treatment-emergent adverse events described as mild; results were presented at ADA 2025 and EASD 2025.
Animal
Company disclosures describe diet-induced obese mouse-model pharmacology supporting the quadruple-agonist weight-loss mechanism; these data were not independently peer-reviewed in the sources examined.
Uncertain
Phase 2 results have so far been communicated through conference abstracts and company press releases, not peer-reviewed full publications; Phase 3 data, long-term safety, and cardiovascular outcomes are lacking.
Key Studies & Findings
Benefits & Effects
muscle-sparing weight loss
clinical
once-daily dosing with or without food
clinical
milder GI side effects than injectable GLP-1s
clinical
quadruple receptor activation for comprehensive metabolic effects
clinical
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
No peer-reviewed full publication of the Phase 2 data yet; conference-abstract and press-release evidence only; NA-931 is described by its developer as a small-molecule agonist, whereas the 'Bioglutide' sold as a research peptide is an unregulated product with no clinical or safety data of its own.
Pharmacology
Company pharmacokinetic data support once-daily oral dosing, with blood levels unaffected by food intake; the mechanism is simultaneous agonism of IGF-1, GLP-1, GIP and glucagon receptors. Full pharmacokinetic parameters are not yet published in peer-reviewed literature.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
50mg
Route: Oral
Half-life: 16 hrs – 1 day
Research Protocols
Starting / Titration
- Dose
- 50mg
- Frequency
- Once daily
- Route
- Oral
Standard dose
- Dose
- 100mg
- Frequency
- Once daily
- Route
- Oral
Maximum clinical dose
- Dose
- 150mg
- Frequency
- Once daily
- Route
- Oral
Research titration protocol
- Dose
- Start 2.5mg, increase 2.5mg weekly
- Frequency
- Once daily
- Route
- Oral (as tolerated)
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Has Bioglutide (NA-931) completed Phase 3?
No. It is in Phase 2; 13-week Phase 2 results were presented at ADA 2025 and EASD 2025, and peer-reviewed publication is pending.
Is the 'Bioglutide' sold as a research peptide the same as the drug candidate?
No. The retail research product is unregulated and has no safety or efficacy data; only the company's regulated drug candidate (NA-931) has clinical trial results.
Research Citations
1
Phase 2 Clinical Trial - Obesity (2024)
(2024)
2
Phase 1 Trial - Safety and PK (2024)
(2024)
3
EASD 2025 Presentation - Phase 2 Results
()
Related Resources
Quick Facts
Mechanism
NA-931 is a small lipophilic molecule derived from cyclic IGF-1 fragment that crosses the blood-brain barrier. Simultaneously activates IGF-1 (muscle preservation, insulin sensitivity), GLP-1 (appetite suppression, insulin secretion), GIP (glucose metabolism, fat storage), and glucagon (energy expenditure, fat oxidation) receptors.
Safety Information
Investigational drug - not yet FDA approved. Start at lower dose (50mg) and titrate up as tolerated. Most common side effects: mild nausea (7.3%), diarrhea (6.3-8.1%). 83% of GI adverse events rated mild or insignificant in trials. No serious drug-related adverse events in Phase 2. Caution with personal/family history of medullary thyroid carcinoma (GLP-1 class concern). Monitor for pancreatitis symptoms (severe abdominal pain). Drug interactions not fully characterized - avoid stacking with other GLP-1 agonists.
Citations
31.Phase 2 Clinical Trial - Obesity (2024)
(2024)
2.Phase 1 Trial - Safety and PK (2024)
(2024)
3.EASD 2025 Presentation - Phase 2 Results
()